Search
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Categories: Vasodilators Used in Cardiac DiseasesSynonyms: DL-prenylamine, N-(3,3-Diphenylpropyl)-alpha-methylphenaethylaminEplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigational+7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) Score were observed. … Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.
Racemethionine
go.drugbank.com/drugs/DB13972ApprovedA preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.
Mixtures: INYECCIÓN DE TRAVASOL 10 % SIN ELECTROLITOS, TRAVASOL PLUS 15% LIBRE DE BISULFITOSynonyms: DL-Methionine, DL-MethioninumVarenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalIn addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine DependenceCilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalIt is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States. … Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs.
Categories: Agents Acting on the Renin-Angiotensin SystemSomapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666] … [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Sodium feredetate
go.drugbank.com/drugs/DB13381ApprovedMixtures: Cavan-EC SOD DHA, Cavan-EC SOD DHACategories: Compounds used in a research, industrial, or household settingPegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigational[A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in
Trifarotene
go.drugbank.com/drugs/DB12808ApprovedInvestigationalTrifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. … [A187081] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects
Categories: Retinoids for Topical Use in Acne